All stock lists
Unlock the score
enGene Therapeutics Inc. (NASDAQ:ENGN)
CA · Delayed Price · Currency is USD
Healthcare · Biotechnology
1.59+0.03 (+1.92%)
Insider Score
/ 100
ENGN Insider Score
enGene Therapeutics Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
ENGN Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 178.00 K | 180.00 K | 189.00 K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -178.00 K | -180.00 K | -189.00 K | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 13.92 M | 9.77 M | 8.93 M | 10.02 M | 6.68 M | 5.98 M |
| R&D Expense | 20.09 M | 22.20 M | 22.25 M | 31.72 M | 22.57 M | 20.21 M |
| Operating Expenses | 34.01 M | 31.97 M | 31.00 M | 39.48 M | 29.95 M | 27.12 M |
| Operating Income | 34.01 M | 31.97 M | -31.18 M | -39.48 M | -29.95 M | -27.12 M |
| Pretax Income | 32.50 M | 30.23 M | -29.75 M | -38.38 M | -28.75 M | -25.57 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | -497.00 K | 239.00 K | 240.00 K |
| Net Income | 32.50 M | 30.23 M | -29.75 M | -37.88 M | -28.99 M | -25.82 M |
| EPS (Basic) | 0.47 | 0.43 | -0.44 | -0.74 | -0.57 | -0.51 |
| EPS (Diluted) | 0.47 | 0.43 | -0.44 | -0.74 | -0.57 | -0.51 |
| Shares Outstanding | 69.73 M | 69.72 M | 67.26 M | 51.30 M | 51.10 M | 51.02 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.